Codexis, Takeda expand gene therapy collaboration

By The Science Advisory Board staff writers

June 10, 2021 -- Codexis has expanded its strategic collaboration and license agreement with Takeda Pharmaceutical for the research and development of an additional gene therapy for a lysosomal storage disorder, bringing the total number of programs under the agreement to four.

Under the original agreement, Codexis used its CodeEvolver protein engineering platform to generate novel gene sequences that encode enzyme variants with enhanced efficacy. Subsequently, Takeda has combined the improved transgenes with its gene therapy capabilities to develop novel candidates for the treatment of rare genetic disorders.

Takeda had the contractual option to expand the collaboration into a fourth program. Codexis is responsible for the creation of novel enzyme sequences for advancement as gene therapies into preclinical development.

Takeda is responsible for the preclinical and clinical development and commercialization of gene therapy products resulting from the collaboration programs. Codexis is eligible to receive an upfront payment, reimbursement for research and development fees, development and commercial milestone payments, and royalties in the low- to mid-single-digits on sales of any commercial products developed through the program.

BridGene, Takeda partner to discover drugs using chemoproteomics
BridGene Biosciences has entered a strategic research collaboration and licensing agreement with Takeda Pharmaceutical to establish up to five drug discovery...
Evotec, Takeda partner on RNA-targeting drug discovery, development
Evotec has entered into an alliance with Takeda Pharmaceutical with the goal of discovering and developing RNA-targeting small-molecule therapeutics for...
Takeda to acquire Maverick Therapeutics
Takeda Pharmaceutical has exercised its option to purchase T cell-targeted immunotherapy developer Maverick Therapeutics for up to $525 million in...
Startup Ensoma launches with gene therapy vector platform
A new genomic medicine startup called Ensoma made its corporate debut this week, raising $70 million in financing and entering into a strategic collaboration...

Copyright © 2021

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter